Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.
Daruka MahadevanMark C LanasaCharles FarberManjari PandeyMaria WheldenSusan J FaasTerrie UleryAnjli KukrejaLan LiCamille L BedrosianXiaoping ZhangLeonard T HeffnerPublished in: Journal for immunotherapy of cancer (2019)
ClinicalTrials.gov, NCT00648739 registered April 1, 2008.